NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Why:Â Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"). ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON JASPER THERAPEUTICS, INC. (JSPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 7, 2025, Jasper released an update on its Phas. ...

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”), Chronic Inducible Urticaria (“CIndU”), and Asthma. For more informatio ...

NEW YORK--(BUSINESS WIRE)---- $JSPR #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgi ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or misleading state ...

ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Jasper’s business, operations, and compliance policies, including allegations that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on ...

公司诉讼事件 - 投资者有机会牵头针对Jasper Therapeutics公司的证券欺诈诉讼 [1] - 诉讼由Schall Law Firm律师事务所代理 [1]

NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. SO WHAT: If you purchased Jasper Therapeutics secu ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period†). Jasper is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigat. ...

集体诉讼事件 - 集体诉讼代表在2023年11月30日至2025年7月3日期间购买或收购Jasper Therapeutics公司证券的个人和实体提起 [1] - 诉讼指控公司未能披露其缺乏确保第三方制造商完全符合cGMP法规的控制和程序 [2] - 上述失败增加了正在进行的研究结果被混淆的风险 从而对包括briquilimab在内的公司产品的监管和商业前景产生负面影响 [2] - 上述情况增加了采取破坏性成本削减措施的可能性 [2] - 因此公司的业务和/或财务前景以及briquilimab的临床和/或商业前景被夸大 [2] 股价影响 - 2025年7月7日真相揭露后 Jasper股价下跌每股373美元 跌幅551% 收盘报每股304美元 [3] 公司业务 - Jasper是一家临床阶段生物技术公司 专注于开发针对肥大细胞驱动疾病的治疗方法 如慢性自发性荨麻疹(CSU) 慢性诱导性荨麻疹(CIndU)和哮喘 [1] - 公司的主要产品候选药物是briquilimab [2]